WO2003103681A3 - Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziiert sind - Google Patents

Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziiert sind Download PDF

Info

Publication number
WO2003103681A3
WO2003103681A3 PCT/EP2003/005990 EP0305990W WO03103681A3 WO 2003103681 A3 WO2003103681 A3 WO 2003103681A3 EP 0305990 W EP0305990 W EP 0305990W WO 03103681 A3 WO03103681 A3 WO 03103681A3
Authority
WO
WIPO (PCT)
Prior art keywords
orally
medicament
treatment
production
bone marrow
Prior art date
Application number
PCT/EP2003/005990
Other languages
English (en)
French (fr)
Other versions
WO2003103681A2 (de
Inventor
Cornelia Norden
Nicolas Aigner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Priority to KR10-2004-7019813A priority Critical patent/KR20050007591A/ko
Priority to CA002488861A priority patent/CA2488861A1/en
Priority to JP2004510800A priority patent/JP2005536476A/ja
Priority to AU2003236715A priority patent/AU2003236715A1/en
Priority to EP03735573A priority patent/EP1515728A2/de
Publication of WO2003103681A2 publication Critical patent/WO2003103681A2/de
Publication of WO2003103681A3 publication Critical patent/WO2003103681A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft die Verwendung von oral verfügbaren Prostazyklinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind.
PCT/EP2003/005990 2002-06-06 2003-06-05 Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziert sind WO2003103681A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR10-2004-7019813A KR20050007591A (ko) 2002-06-06 2003-06-05 경구 사용가능한 프로스타시클린 유도체의 골수 부종과연관된 질환 상태 치료용 의약 제조에 있어서의 용도
CA002488861A CA2488861A1 (en) 2002-06-06 2003-06-05 Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema
JP2004510800A JP2005536476A (ja) 2002-06-06 2003-06-05 骨髄浮腫に関連する病気治療用医薬製剤の製造のための経口用プロスタサイクリン誘導体の使用
AU2003236715A AU2003236715A1 (en) 2002-06-06 2003-06-05 Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema
EP03735573A EP1515728A2 (de) 2002-06-06 2003-06-05 Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziiert sind

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225551.2 2002-06-06
DE10225551A DE10225551A1 (de) 2002-06-06 2002-06-06 Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind

Publications (2)

Publication Number Publication Date
WO2003103681A2 WO2003103681A2 (de) 2003-12-18
WO2003103681A3 true WO2003103681A3 (de) 2004-03-25

Family

ID=29594336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/005990 WO2003103681A2 (de) 2002-06-06 2003-06-05 Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziert sind

Country Status (9)

Country Link
EP (1) EP1515728A2 (de)
JP (1) JP2005536476A (de)
KR (1) KR20050007591A (de)
CN (1) CN1658882A (de)
AU (1) AU2003236715A1 (de)
CA (1) CA2488861A1 (de)
DE (1) DE10225551A1 (de)
WO (1) WO2003103681A2 (de)
ZA (1) ZA200500097B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641393C (en) * 2006-02-03 2014-12-16 Scidose Llc Novel epoprostenol formulation and method of making thereof
TWI520740B (zh) * 2011-02-02 2016-02-11 模範健康科技私人企業有限公司 利用多硫酸化多醣之骨髓水腫（水腫）的治療
JP2020531549A (ja) * 2017-08-31 2020-11-05 シャリテ−ウニベルジテーツメディツィン ベルリン 易感染性患者における筋骨格系損傷の治癒不良を防ぐための免疫調節

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886788A (en) * 1986-03-07 1989-12-12 Schering Aktiengesellschaft Cyclodextrin clathrates of carbacyclin derivatives and their use as medicinal agents
WO1994003175A1 (de) * 1992-08-07 1994-02-17 Schering Aktiengesellschaft Verwendung von prostanderivaten zur herstellung eines arzneimittels zur behandlung der chronischen polyarthritis
EP1016408A1 (de) * 1997-09-16 2000-07-05 Toray Industries, Inc. C-c chemokine produktionsinhibitoren
WO2002026194A2 (en) * 2000-09-28 2002-04-04 Non-Invasive Monitoring Systems, Inc. External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886788A (en) * 1986-03-07 1989-12-12 Schering Aktiengesellschaft Cyclodextrin clathrates of carbacyclin derivatives and their use as medicinal agents
WO1994003175A1 (de) * 1992-08-07 1994-02-17 Schering Aktiengesellschaft Verwendung von prostanderivaten zur herstellung eines arzneimittels zur behandlung der chronischen polyarthritis
EP1016408A1 (de) * 1997-09-16 2000-07-05 Toray Industries, Inc. C-c chemokine produktionsinhibitoren
WO2002026194A2 (en) * 2000-09-28 2002-04-04 Non-Invasive Monitoring Systems, Inc. External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AIGNER N ET AL: "Treatment of bone-marrow oedema of the talus with the prostacyclin analogue iloprost", JOURNAL OF BONE AND JOINT SURGERY - SERIES B 2001 UNITED KINGDOM, vol. 83, no. 6, 2001, pages 855 - 858, XP009016504, ISSN: 0301-620X *
GAO INO K ET AL: "A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: Cytokine modulation, safety, and clinical effects.", RHEUMATOLOGY INTERNATIONAL, vol. 22, no. 2, June 2002 (2002-06-01), pages 45 - 51, XP002252979, ISSN: 0172-8172 *
MCQUEEN F M: "Magnetic resonance imaging in early inflammatory arthritis: What is its role?", RHEUMATOLOGY 2000 UNITED KINGDOM, vol. 39, no. 7, 2000, pages 700 - 706, XP002252981, ISSN: 1462-0324 *
PETJE G ET AL: "Aseptic bone necrosis in childhood. Diagnosis and treatment", ORTHOPADE 2002 GERMANY, vol. 31, no. 10, 2002, pages 1027 - 1038, XP002252980, ISSN: 0085-4530 *

Also Published As

Publication number Publication date
CA2488861A1 (en) 2003-12-18
CN1658882A (zh) 2005-08-24
DE10225551A1 (de) 2003-12-24
WO2003103681A2 (de) 2003-12-18
ZA200500097B (en) 2006-06-28
JP2005536476A (ja) 2005-12-02
KR20050007591A (ko) 2005-01-19
AU2003236715A1 (en) 2003-12-22
EP1515728A2 (de) 2005-03-23

Similar Documents

Publication Publication Date Title
MY127290A (en) New use of flibanserin
PL1646634T3 (pl) Zastosowanie rapamycyny i pochodnych rapamycyny w leczeniu utraty kości
MXPA06000123A (es) Suspension aislante de apoyo central de resorte rapido de plastico y metodo para fabricar y ensamblar el mismo.
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
HRP20080175T3 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
YU21702A (sh) Supstituisani indoli za moduliranje nfkb aktivnosti
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
MY136269A (en) Novel diphenylazetidinone, process for its preparation, medicaments comprising this compound and their use
HK1068274A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontinence
SI1594885T1 (sl) Zdravilo za inhibiranje rasti tumorjev
SG165159A1 (en) Process for preparing 6-alkylidene penem derivatives
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
DE59904180D1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
WO2003103681A3 (de) Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziiert sind
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
TW200501970A (en) Use of PVP-iodine liposomes for treatment of acne
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
TW200509987A (en) Use of PVP-iodine liposomes for treatment of Herpes
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
EP1513550A4 (de) Neues bakterium zur behandlung von erkrankungen
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
MXPA04001856A (es) Indan-1-oles c2-sustituidos y sus derivados, metodo para su produccion y su uso como medicamentos.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2488861

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004510800

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038129760

Country of ref document: CN

Ref document number: 1020047019813

Country of ref document: KR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003735573

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005/00097

Country of ref document: ZA

Ref document number: 200500097

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 1020047019813

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003735573

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003735573

Country of ref document: EP